Uruguay Ships 2,205 lbs of Flower to Mystery Buyer
A 2,205-pound (1,000-kilogram) shipment of high THC medical cannabis left Uruguay in October of 2019, considered the largest flower export ever. To put that into perspective, Germany, the largest importer of marijuana on the planet, buys in total about half that much each month. According to customs documents, Fotmer Life Sciences, a Uruguay based producer, sent the massive amount of weed to a buyer in Portugal for $3.2 million. The price included insurance and freight.What is not known is exactly who purchased the pot, and for what purpose. Portugese officials have declared the information “is not public”, and marketing director for Fotmer Life Sciences Vera Tochetti has stated that her company can not disclose the name of the buyer.
CBD Extracted From Orange Peels Revealed in Japan
Hiro International, a Japanese fruit and fruit juice import company who specializes in extracts such as banana, red bean, and horse placenta, has announced they can now extract CBD from orange peels.
Spokesperson for Hiro International, Ryouske Koseki, also states that orange peel CBD, since it is not derived from hemp, contains 0.0% THC. He claims the two CBD are identical in structure, “With Orange CBD, you get the same ingredient, same effects and there’s no danger in terms of legality. It also provides a different story of CBD for the consumer that sounds better than being derived from the marijuana plant.”
The company had initially created the product for domestic use in Japan, where marijuana is still quite illegal. But the international reception Orange CBD received at CosmeTokyo, a cosmetic trade show, has the company thinking otherwise, “We didn’t expect so many international visitors. This is only the first day and judging by the reaction, there are a lot of people who are interested. Now we will have to decide if we still want to focus on the domestic market or take on overseas as well.”
Hiro International, a Japanese fruit and fruit juice import company who specializes in extracts such as banana, red bean, and horse placenta, has announced they can now extract CBD from orange peels. Spokesperson for Hiro International, Ryouske Koseki, also states that orange peel CBD, since it is not derived from hemp, contains 0.0% THC. He claims the two CBD are identical in structure, “With Orange CBD, you get the same ingredient, same effects and there’s no danger in terms of legality. It also provides a different story of CBD for the consumer that sounds better than being derived from the marijuana plant.”
The company had initially created the product for domestic use in Japan, where marijuana is still quite illegal. But the international reception Orange CBD received at CosmeTokyo, a cosmetic trade show, has the company thinking otherwise, “We didn’t expect so many international visitors. This is only the first day and judging by the reaction, there are a lot of people who are interested. Now we will have to decide if we still want to focus on the domestic market or take on overseas as well.”
Canada’s Aurora Buys U.S. Based Reliva, Sees ‘Surge’
“It’s immediate access into the world’s largest cannabinoid market,” said Aurora Cannabis Executive Chairman and interim CEO Micheal Singer of the purchase by his company of Reliva, “I think the Reliva acquisition is a responsible strategic entry into the U.S. market; and for Aurora, delivers a key aspect of our reset plan.” Reliva has access to 20,000 retail locations in the U.S., including Circle K convenience stores.
In the deal, Reliva stakeholders will receive $40 million in Aurora shares. These shares are being touted as surging 120% since May 14 when Aurora announced a narrower quarter-over-quarter loss, relative to the 90% loss in value the stocks have seen over the past 12 months.
In February 2020 Terry Booth retired from Aurora as CEO, and the company laid off 500 employees while writing down approximately $700 million in product and equipment.
“It’s immediate access into the world’s largest cannabinoid market,” said Aurora Cannabis Executive Chairman and interim CEO Micheal Singer of the purchase by his company of Reliva, “I think the Reliva acquisition is a responsible strategic entry into the U.S. market; and for Aurora, delivers a key aspect of our reset plan.” Reliva has access to 20,000 retail locations in the U.S., including Circle K convenience stores.
In the deal, Reliva stakeholders will receive $40 million in Aurora shares. These shares are being touted as surging 120% since May 14 when Aurora announced a narrower quarter-over-quarter loss, relative to the 90% loss in value the stocks have seen over the past 12 months.
In February 2020 Terry Booth retired from Aurora as CEO, and the company laid off 500 employees while writing down approximately $700 million in product and equipment.
Newborn in England First to Use Cannabis Treatment
Oscar Parodi was born on March 11 at Norfolk and Norwich University Hospital, in critical condition, and was immediately transferred to the neonatal intensive care unit for a 72 hour cooling therapy. Chelsea, his mother, explains what happened next, “I was approached after the birth about taking part in this study and I consulted my mum and my brother who is training to be a paramedic. It was hard but I wanted to do everything I could to help my baby boy. Oscar was in the hospital for nine days and he was being monitored 24/7.”
Professor Paul Clarke, a consultant neonatologist at NNUH, was excited when she accepted, “This is the first time a cannabis-derived medicine has been tested intravenously in human babies. It is hoped that it will be good for preventing seizures and protecting the brains of newborn babies with HIE.” Neonatal hypoxic ischemic encephalopathy (HIE) is a condition which causes brain injury to babies.
A second child has since been born and placed on the trial, which consists of standard hypothermia treatment where the whole body is cooled down to 33.5c, then a single dose of the trial drug, or placebo, followed by tests. The trial also uses more advanced brainwave monitors on the babies, ensuring any seizures or changes in activity are noticed. Clarke was sure to explain, “As with any study of a new medicine there may be unexpected side effects and unknown risks. With this in mind the trial has been carefully desgined to make it as safe as possible, and so we are only giving the babies a minscule dose at the beginning, and we monitor them even more closely than usual.”
Oscar Parodi was born on March 11 at Norfolk and Norwich University Hospital, in critical condition, and was immediately transferred to the neonatal intensive care unit for a 72 hour cooling therapy. Chelsea, his mother, explains what happened next, “I was approached after the birth about taking part in this study and I consulted my mum and my brother who is training to be a paramedic. It was hard but I wanted to do everything I could to help my baby boy. Oscar was in the hospital for nine days and he was being monitored 24/7.”
Professor Paul Clarke, a consultant neonatologist at NNUH, was excited when she accepted, “This is the first time a cannabis-derived medicine has been tested intravenously in human babies. It is hoped that it will be good for preventing seizures and protecting the brains of newborn babies with HIE.” Neonatal hypoxic ischemic encephalopathy (HIE) is a condition which causes brain injury to babies.
A second child has since been born and placed on the trial, which consists of standard hypothermia treatment where the whole body is cooled down to 33.5c, then a single dose of the trial drug, or placebo, followed by tests. The trial also uses more advanced brainwave monitors on the babies, ensuring any seizures or changes in activity are noticed. Clarke was sure to explain, “As with any study of a new medicine there may be unexpected side effects and unknown risks. With this in mind the trial has been carefully desgined to make it as safe as possible, and so we are only giving the babies a minscule dose at the beginning, and we monitor them even more closely than usual.”
